Physician profile
Sumit Bector
NPI 1487831202
$5,736.99
in general payments reported to CMS, 2019-2025
30 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $37.15 · 2021: $128 · 2022: $443 · 2023: $1,815 · 2024: $1,287 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155 · Consulting Fee: $290 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,155.12 |
| Consulting Fee | $290.00 |
| Education | $112.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,258.16 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $822.32 | 2019-2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.18 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $330.99 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $290.00 | 2023 | Benlysta |
| Horizon Therapeutics Plc | $282.66 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $264.62 | 2024-2025 | Ozempic |
| Calliditas Therapeutics US INC. | $203.77 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $190.65 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $181.25 | 2022-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $173.28 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $172.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.44 | 2024-2025 | |
| Akebia Therapeutics INC | $116.42 | 2019-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $114.21 | 2024-2025 | Acthar |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $106.13 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $105.99 | 2023 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $99.46 | 2019 | |
| Vifor Pharma, INC. | $84.00 | 2019-2023 | Veltassa |
| Biotronik INC. | $82.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $65.01 | 2024-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $34.19 | 2023 | Rayaldee |
| Abbott Laboratories | $32.10 | 2025 | Cardiomems |
| Genentech USA, INC. | $27.19 | 2025 | Gazyva |
| Aurinia Pharma U.S., INC. | $26.15 | 2024 | Lupkynis |
| Daiichi Sankyo INC. | $22.67 | 2021 | |
| Lilly USA, LLC | $20.36 | 2025 | Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $20.26 | 2023 | Keveyis |
| Scpharmaceuticals INC. | $20.12 | 2025 | |
| Shire North American Group INC | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.